trending Market Intelligence /marketintelligence/en/news-insights/trending/mqccj3jcudklxdlv0bs2tg2 content esgSubNav
In This List

Aurora Cannabis' international push; outgoing Pfizer CEO leaves legacy of growth

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Aurora Cannabis' international push; outgoing Pfizer CEO leaves legacy of growth

Aurora Cannabis pushes into international market with relentless acquisitions

The Canadian cannabis producer/distributor has been snapping up companies in an aggressive M&A strategy as it seeks to position itself in the growing medical marijuana market and despite a lack of established science for most treatments.

Outgoing Pfizer CEO leaves successor legacy of growth and biosimilar woes

Ian Read brought Pfizer Inc. from $15 a share when he entered the position at the end of 2010 to a little more than $44 at market close the Friday before he announced he was stepping down, a 170% increase.

Radius Health CEO talks company vision, ups and downs of Tymlos launch

Radius Health Inc. president and CEO Jesper Høiland reflects on his first year with the company and discusses new additions to the company's pipeline, including treatments for metastatic breast cancer.

Old antibiotic may selectively kill lethal skin cancer cells, researchers find

Despite the lack of research being undertaken by large pharmaceutical companies into new antibiotics, scientists have discovered that by repurposing older versions, progress has been made against a type of aggressive skin cancer.

Bill to combat US opioid epidemic heads to Trump's desk after Senate endorsement

A 660-page landmark bill to address the U.S. opioid crisis is headed to President Donald Trump's desk for his signature after the Senate endorsed the legislative package in a 98-to-1 vote.

Hospital CEOs call on Congress to protect discount drug-pricing program

Over 700 CEOs representing U.S. hospitals and health systems are urging Congress to protect the 340B drug pricing program, which had its payment rates significantly reduced in 2017 by the Centers for Medicare and Medicaid Services.

Of Mice Not Men: Gene therapy helps paw function in rats, viruses target cancer

In this week's column, scientists found that rats with injuries to the spinal cord can relearn skilled hand movements after being treated with gene therapy; and viruses have shown renewed promise in cancer treatment.

Amid tech boom, VC investment soars as consumers pressure healthcare to digitize

Reports from Mercom and Ernst & Young suggest that the future in healthcare lies in technology, especially as the new generation of "super consumers" demand greater affordability, accessibility and convenience.

Eli Lilly's $50M oral diabetes therapy gives Novo a GLP-1 competitor

Eli Lilly and Co. bought a preclinical oral diabetes drug for $50 million from Roche Holding AG's Chugai Pharmaceutical Co. Ltd., notching a foothold behind diabetes rival Novo Nordisk A/S to enter that coveted market.

Capitol Checkup: Opioid bill nears finish line; Congress funds HHS

In a rare bipartisan move, the U.S. House adopted a sweeping legislative package aimed at combating America's opioid epidemic. Meanwhile, lawmakers provided another $6.7 billion to Health and Human Services to address the crisis.

CMS head defends Arkansas' Medicaid work requirements despite coverage loss risk

Seema Verma, the Centers for Medicare and Medicaid Services administrator, defended Medicaid work requirements in a Sept. 27 speech, saying the agency is close to approving another state's request.